BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 9625763)

  • 21. A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation.
    Kean LS; Durham MM; Adams AB; Hsu LL; Perry JR; Dillehay D; Pearson TC; Waller EK; Larsen CP; Archer DR
    Blood; 2002 Mar; 99(5):1840-9. PubMed ID: 11861303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful allogeneic neonatal bone marrow transplantation devoid of myeloablation requires costimulatory blockade.
    Soper BW; Lessard MD; Jude CD; Schuldt AJ; Bunte RM; Barker JE
    J Immunol; 2003 Sep; 171(6):3270-7. PubMed ID: 12960357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined host-conditioning with CTLA4-Ig, tacrolimus, anti-lymphocyte serum, and low-dose radiation leads to stable mixed hematopoietic chimerism.
    Li S; Thanikachalam M; Pang M; Carreno M; Aitouche A; Pham SM
    Exp Hematol; 2001 Apr; 29(4):534-41. PubMed ID: 11301194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection.
    Tanaka K; Albin MJ; Yuan X; Yamaura K; Habicht A; Murayama T; Grimm M; Waaga AM; Ueno T; Padera RF; Yagita H; Azuma M; Shin T; Blazar BR; Rothstein DM; Sayegh MH; Najafian N
    J Immunol; 2007 Oct; 179(8):5204-10. PubMed ID: 17911605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mixed allogeneic reconstitution (A+B----A) to induce donor-specific transplantation tolerance. Permanent acceptance of a simultaneous donor skin graft.
    Ildstad ST; Wren SM; Oh E; Hronakes ML
    Transplantation; 1991 Jun; 51(6):1262-7. PubMed ID: 1828637
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A synthetic CD4-CDR3 peptide analog enhances bone marrow engraftment across major histocompatibility barriers.
    Koch U; Korngold R
    Blood; 1997 Apr; 89(8):2880-90. PubMed ID: 9108408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reconstitution ratio is critical for alloreactive T cell deletion and skin graft survival in mixed bone marrow chimeras.
    Taniguchi H; Abe M; Shirai T; Fukao K; Nakauchi H
    J Immunol; 1995 Dec; 155(12):5631-6. PubMed ID: 7499847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Costimulation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression.
    Adams AB; Durham MM; Kean L; Shirasugi N; Ha J; Williams MA; Rees PA; Cheung MC; Mittelstaedt S; Bingaman AW; Archer DR; Pearson TC; Waller EK; Larsen CP
    J Immunol; 2001 Jul; 167(2):1103-11. PubMed ID: 11441122
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combinations of anti-LFA-1, everolimus, anti-CD40 ligand, and allogeneic bone marrow induce central transplantation tolerance through hemopoietic chimerism, including protection from chronic heart allograft rejection.
    Metzler B; Gfeller P; Bigaud M; Li J; Wieczorek G; Heusser C; Lake P; Katopodis A
    J Immunol; 2004 Dec; 173(11):7025-36. PubMed ID: 15557200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Skin allograft maintenance in a new synchimeric model system of tolerance.
    Iwakoshi NN; Markees TG; Turgeon N; Thornley T; Cuthbert A; Leif J; Phillips NE; Mordes JP; Greiner DL; Rossini AA
    J Immunol; 2001 Dec; 167(11):6623-30. PubMed ID: 11714833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cutting edge: administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning.
    Durham MM; Bingaman AW; Adams AB; Ha J; Waitze SY; Pearson TC; Larsen CP
    J Immunol; 2000 Jul; 165(1):1-4. PubMed ID: 10861026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms of early peripheral CD4 T-cell tolerance induction by anti-CD154 monoclonal antibody and allogeneic bone marrow transplantation: evidence for anergy and deletion but not regulatory cells.
    Kurtz J; Shaffer J; Lie A; Anosova N; Benichou G; Sykes M
    Blood; 2004 Jun; 103(11):4336-43. PubMed ID: 14962909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of intrathymic clonal deletion and peripheral anergy in transplantation tolerance induced by bone marrow transplantation in mice conditioned with a nonmyeloablative regimen.
    Tomita Y; Khan A; Sykes M
    J Immunol; 1994 Aug; 153(3):1087-98. PubMed ID: 8027542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CTLA4-Ig-based conditioning regimen to induce tolerance to cardiac allografts.
    Li S; Salgar SK; Thanikachalam M; Murdock AD; Gammie JS; Demetris AJ; Zeevi A; Pham SM
    J Surg Res; 2006 Dec; 136(2):238-46. PubMed ID: 17046021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant.
    Storb R; Yu C; Zaucha JM; Deeg HJ; Georges G; Kiem HP; Nash RA; McSweeney PA; Wagner JL
    Blood; 1999 Oct; 94(7):2523-9. PubMed ID: 10498626
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapamycin and CTLA4Ig synergize to induce stable mixed chimerism without the need for CD40 blockade.
    Pilat N; Klaus C; Schwarz C; Hock K; Oberhuber R; Schwaiger E; Gattringer M; Ramsey H; Baranyi U; Zelger B; Brandacher G; Wrba F; Wekerle T
    Am J Transplant; 2015 Jun; 15(6):1568-79. PubMed ID: 25783859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined Anti-CD154/CTLA4Ig Costimulation Blockade-Based Therapy Induces Donor-Specific Tolerance to Vascularized Osteomyocutaneous Allografts.
    Lin CH; Wang YL; Anggelia MR; Chuang WY; Cheng HY; Mao Q; Zelken JA; Lin CH; Zheng XX; Lee WP; Brandacher G
    Am J Transplant; 2016 Jul; 16(7):2030-41. PubMed ID: 26914847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blockade of the CD40/CD154 pathway enhances T-cell-depleted allogeneic bone marrow engraftment under nonmyeloablative and irradiation-free conditioning therapy.
    Pan Y; Luo B; Sozen H; Kalscheuer H; Blazar BR; Sutherland DE; Hering BJ; Guo Z
    Transplantation; 2003 Jul; 76(1):216-24. PubMed ID: 12865813
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion.
    Lin H; Bolling SF; Linsley PS; Wei RQ; Gordon D; Thompson CB; Turka LA
    J Exp Med; 1993 Nov; 178(5):1801-6. PubMed ID: 8228826
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term acceptance of composite tissue allografts through mixed chimerism and CD28 blockade.
    Foster RD; Pham S; Li S; Aitouche A
    Transplantation; 2003 Sep; 76(6):988-94. PubMed ID: 14508367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.